T2 Biosystems achieves successful defense against key patent

T2 Biosystems announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union. The opposition was filed in May 2023 with the European Patent Office, EPO, by bioMerieux and a strawman representing other undisclosed firm(s) against T2 Biosystems’ granted European Patent No. 3 443 124, which relates to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This patent is part of T2 Biosystems’ intellectual property portfolio surrounding its proprietary direct-from-whole blood pathogen detection method. The Opposition Division of the EPO held a public hearing on September 19, 2024, and ruled such that T2 Biosystems’ strong IP position on the detection of pathogens directly from whole blood was maintained.